CLINICAL PRACTICE GUIDELINE FOR MANAGEMENT OF ANAPHYLAXIS EMERGENCY DEPARTMENT, URGENT CARE, INPATIENT, AMBULATORY

Revised 3/2023, 2/2022, 06/2020 ORIGINAL 2/2019 Page 1 of 2

	Raj	oid Recognition of Anap	ohylaxis	
		Excludes Suspected Blood Transfusion Reactions. Refer to Clinical Policy 7-00 Action for Suspected Transfusion Reaction		
Skin/Mucosal • Hives • Flush • Rash • Itchin • Tearing or red eyes • Swelling (e.g. lips/tongue/ eyes)	• Cough • Hoarsenes • Wheeze • Congestion	• Tachy/bradycardia • Syncope	 Abdominal pain Vomiting Diarrhea Swallowing problem 	CNS • Headache • Vision changes • Dizziness • Seizures • Confusion • Altered mental status
ABCs	Call for Assistance	Rescue Medications	-Injectable epi available in c medication room	ode cart, override in omnicell, or
 Immediately stop exposure to suspected medication or agent Manage airway, breathing, and circulation Apply O2 via non- rebreather and keep sats ≥94% Place patient in supine position, unless patient in respiratory distress 	In hospital: • Notify Provider • Emergent: CODE BLUE 5-6161 • Urgent: RAPID RESPONSE TEAM 5-TEAM (5-8326) Outpatient/Urgent Care: • Alert on-call Provider if not present • Emergent: 9-911 • Urgent; or, cannot observe for 4+ hours: Transfer Center ED: • Triage acuity blue	 Administer IM EPINEPHrine (epi), within 5 minutes, in the anterolateral thigh Concentration: 1mg/mL Quick Dose epi IM: <10kg: 0.1mg= 0.1mL IM 10-30kg: 0.15mg= 0.15mL IM >30kg: 0.3mg= 0.3mL IM 	 Failure to respond to first dose of epi: Administer another dose of IM epi (can be administered every 5- 15 minutes for rapid progression of symptoms OR failure to respond) Obtain IV/IO access If hypotensive administer isotonic IV fluid, 20mL/kg, rapidly, over 5-10 minutes If wheezing: Albuterol 	PALS criteria for hypotension based on Systolic Blood Pressure (SBP):AGESBPNeonates<60

Additional Medication/ Interventions See page 2 for dosing

If upper airway obstruction/ stridor: Consider racemic EPINEPHrine

H1 blocker recommended for cutaneous symptoms such as urticaria and pruritis. If using, liquid formulation preferred to optimize absorption:

Give any one of the following:

- Cetirizine (Zyrtec) PO preferred over DiphenhydrAMINE (Benadryl) if readily available, otherwise Benadryl PO
- DiphenhydrAMINE (Benadryl) PO/IV/IM (IV only if unable to take PO)
- HydrOXYzine IM/PO
- Loratidine PO

H2 Blockers are not routinely indicated – may consider if GI symptoms

Observation/Admission Criteria

Observation Period

 If NO hypotension, observe for a minimum of 4 hours prior to discharge

 Patients with resolved respiratory compromise and/or hypotension, observe 6-8 hours prior to discharge

Admission Criteria

- Required more than 1 dose of epi
- Required a fluid bolus
- Persistent symptoms >4 hours
- Worsening symptoms
- History of severe biphasic reaction
- History of severe asthma

Consider PICU Admission

- Hemodynamic instability
- Respiratory failure
- Continued/recurrent airway compromise
- Requiring any of the following:
 - >40mL/kg volume
 - >2 doses of IM epi
 - epi •Heliox
 - •>1 continuous neb •NIPPV

Discharge Planning

Prior to Discharge

- Consult allergy for inpatients who have difficult to treat reactions (such as biphasic or prolonged reactions) or high risk asthma
- Consider Case Management consult to assist with filling prescription for epinephrine autoinjectors

Education and Prescriptions

- 1. Prescribe epinephrine autoinjector
- 2. Prescribe other meds as indicated (see page 2)
- 3. Follow up with Allergist in 3-4 weeks
- 4. Epinephrine autoinjector video

Developed through the efforts of Children's Healthcare of Atlanta and physicians on Children's medical staff in the interest of advancing pediatric healthcare. This is a general guideline and does not represent a professional care standard governing providers' obligation to patients. Ultimately the patient's physician must determine the most appropriate care. © 2019 Children's Healthcare of Atlanta, Inc.

Pressors

CLINICAL PRACTICE GUIDELINE FOR MANAGEMENT OF ANAPHYLAXIS EMERGENCY DEPARTMENT, URGENT CARE, INPATIENT, AMBULATORY Revised 3/2023, 2/2022, 06/2020 ORIGINAL 2/2019 Page 2 of 2



	Medication	Standard mg/kg Dose	Frequency			
	Give any one of the following:					
	Cetirizine <i>(Zyrtec)</i> *Preferred over DiphenhydrAMINE if readily available, otherwise Benadryl PO	6-23 months old: 2.5mg PO 24 months-5 years old: 2.5-5mg PO ≥6 years old: 5-10mg PO	Q24H PRN cutaneous symptoms (urticaria, pruritis)			
	DiphenhydrAMINE (Benadryl)	1mg/kg/dose PO/IV/IM Max dose 50mg	Q6H PRN cutaneous symptoms (urticari pruritis)			
	HydrOXYzine (Vistaril)	≤40kg: 0.5mg/kg/dose PO >40kg: 25-50mg PO	Q6H PRN cutaneous symptoms (urticari pruritis)			
	Loratadine <i>(Claritin)</i>	2-6 years old: 5mg PO ≥6 years old: 10mg PO	Q24H PRN cutaneous symptoms (urticaria, pruritis)			
	Medication	Standard mg/kg Dose	Frequency			
	Albuterol	<15kg: Intermittent 2.5mg Continuous 7.5mg/hr ≥15kg: Intermittent 5mg Continuous 15mg/hr	•Q4-6H for 24 hours; <i>then,</i> •Q4-6H PRN for cough/wheezing/difficulty in breathing			
	Steroids are not routinely recommended . They do not appear to affect biphasic reactions in anaphylaxis. May use in specific circumstances such as history of asthma.					
	PrednisoLONE	1mg/kg/dose PO Max dose: 60mg	If clinically indicated: •2-5 day course			
	Dexamethasone	0.6 mg/kg PO (Max dose 16 mg) <12 kg: 4 mg 12 to <15 kg: 8 mg 15 to <25 kg: 12 mg ≥25 kg: 16 mg				
	MethyIPREDNISolone	2mg/kg/dose IV/IM Max dose: 125mg If IV, infuse over 10 minutes				
	Famotidine* (<i>Pepcid</i>) *No clear evidence of benefit from H2 blockers in immediate treatment of anaphylaxis or biphasic	*IV 0.25mg/kg x1 (max dose of 20mg) *Tablet 0.5mg/kg (max dose of 40mg) *Suspension 0.5mg/kg (max dose 40mg)				

Developed through the efforts of Children's Healthcare of Atlanta and physicians on Children's medical staff in the interest of advancing pediatric healthcare. This is a general guideline and does not represent a professional care standard governing providers' obligation to patients. Ultimately the patient's physician must determine the most appropriate care. © 2019 Children's Healthcare of Atlanta, Inc.